Forecasting the consequence of nanoparticles (NPs) and
therapeutically
significant molecules before materializing for human clinical trials
is a mainstay for drug delivery and screening processes. One of the
noteworthy obstacles that has prevented the clinical translation of
NP-based drug delivery systems and novel drugs is the lack of effective
preclinical platforms. As a revolutionary technology, the organ-on-a-chip
(OOC), a coalition of microfluidics and tissue engineering, has surfaced
as an alternative to orthodox screening platforms. OOC technology
recapitulates the structural and physiological features of human organs
along with intercommunications between tissues on a chip. The current
review discusses the concept of microfluidics and confers cutting-edge
fabrication processes for chip designing. We also outlined the advantages
of microfluidics in analyzing NPs in terms of characterization, transport,
and degradation in biological systems. The review further elaborates
the scope and research on translational nanomedicines in human reproductive
organs (testis, placenta, uterus, and menstrual cycle) by taking the
advantages offered by microfluidics and shedding light on their potential
future implications. Finally, we accentuate the existing challenges
for clinical translation and scale-up dynamics for microfluidics chips
and emphasize its future perspectives.